Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 247

1.

Morbidity after antiretroviral therapy initiation in HIV-1-infected children in West Africa: temporal trends and relation to CD4 count.

De Beaudrap P, Boullé C, Lewden C, Gabillard D, Nacro B, Diagbouga S, Fassinou P, Hien H, Laurent C, Msellati P; ANRS 12222 Morbidity/Mortality Study Group.

Pediatr Infect Dis J. 2013 Apr;32(4):354-60. doi: 10.1097/INF.0b013e318278b222.

PMID:
23099424
2.

Impact of antiretroviral therapy on opportunistic infections of HIV-infected children in the therapeutic research, education and AIDS training asia pediatric HIV observational database.

Prasitsuebsai W, Kariminia A, Puthanakit T, Lumbiganon P, Hansudewechakul R, Siew Moy F, Law M, Kumarasamy N, Razali K, Sirisanthana V, Sohn AH, Chokephaibulkit K.

Pediatr Infect Dis J. 2014 Jul;33(7):747-52. doi: 10.1097/INF.0000000000000226.

3.

Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy.

Ylitalo N, Brogly S, Hughes MD, Nachman S, Dankner W, Van Dyke R, Seage GR 3rd; Pediatric AIDS Clincial Trials Group Protocol 219C Team.

Arch Pediatr Adolesc Med. 2006 Aug;160(8):778-87.

PMID:
16894075
4.

Incidence and determinants of new AIDS-defining illnesses after HAART initiation in a Senegalese cohort.

De Beaudrap P, Etard JF, Diouf A, Ndiaye I, Ndèye GF, Sow PS, Ndèye KC, Ecochard R, Delaporte E; ANRS 1215 Study Group.

BMC Infect Dis. 2010 Jun 19;10:179. doi: 10.1186/1471-2334-10-179.

5.
6.

Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.

Viani RM, Araneta MR, Deville JG, Spector SA.

Clin Infect Dis. 2004 Sep 1;39(5):725-31. Epub 2004 Aug 16.

PMID:
15356789
7.

The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.

Nachman S, Gona P, Dankner W, Weinberg A, Yogev R, Gershon A, Rathore M, Read JS, Huang S, Elgie C, Hudgens K, Hughes W.

Pediatrics. 2005 Apr;115(4):e488-94. Epub 2005 Mar 16.

PMID:
15772172
8.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
9.

Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy.

Dankner WM, Lindsey JC, Levin MJ; Pediatric AIDS Clinical Trials Group Protocol Teams 051, 128, 138, 144, 152, 179, 190, 220, 240, 245, 254, 300 and 327.

Pediatr Infect Dis J. 2001 Jan;20(1):40-8.

PMID:
11176565
10.

Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004.

Nesheim SR, Kapogiannis BG, Soe MM, Sullivan KM, Abrams E, Farley J, Palumbo P, Koenig LJ, Bulterys M.

Pediatrics. 2007 Jul;120(1):100-9.

PMID:
17606567
11.
12.

The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy.

d'Arminio Monforte A, Sabin CA, Phillips A, Sterne J, May M, Justice A, Dabis F, Grabar S, Ledergerber B, Gill J, Reiss P, Egger M; Antiretroviral Therapy Cohort Collaboration.

Arch Intern Med. 2005 Feb 28;165(4):416-23. Erratum in: Arch Intern Med. 2005 May 23;165(10):1200.

PMID:
15738371
13.

Opportunistic infections and other AIDS-defining illnesses in Poland in 2000-2002.

Podlasin RB, Wiercinska-Drapalo A, Olczak A, Beniowski M, Smiatacz T, Malolepsza E, Juszczyk J, Leszczyszyn-Pynka M, Mach T, Mian M, Knysz B, Horban A.

Infection. 2006 Aug;34(4):196-200.

PMID:
16896577
14.

Opportunistic infections and organ-specific diseases in HIV-1-infected children: a cohort study (1990-2006).

Guillén S, García San Miguel L, Resino S, Bellón JM, González I, Jiménez de Ory S, Muñoz-Fernández MA, Navarro ML, Gurbindo MD, de José MI, Mellado MJ, Martín-Fontelos P, Gonzalez-Tomé MI, Martinez J, Beceiro J, Roa MA, Ramos JT; Madrid Group for Research on Pediatric HIV Infection.

HIV Med. 2010 Apr;11(4):245-52. doi: 10.1111/j.1468-1293.2009.00768.x. Epub 2009 Dec 28.

15.

Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.

Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kumar PN, Mintz L, Wallach FR, Nemo GJ; Viral Activation Transfusion Study Investigators.

Ann Intern Med. 2001 Jul 3;135(1):17-26.

PMID:
11434728
16.

Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa.

Moh R, Danel C, Messou E, Ouassa T, Gabillard D, Anzian A, Abo Y, Salamon R, Bissagnene E, Seyler C, Eholié S, Anglaret X.

AIDS. 2007 Nov 30;21(18):2483-91.

PMID:
18025885
17.

[Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].

Pozio E.

Parassitologia. 2004 Jun;46(1-2):89-93. Review. Italian.

PMID:
15305694
18.

Clinical spectrum, morbidity, and mortality of acquired immunodeficiency syndrome in Taiwan: a 5-year prospective study.

Hung CC, Chen MY, Hsieh SM, Sheng WH, Chang SC.

J Acquir Immune Defic Syndr. 2000 Aug 1;24(4):378-85.

PMID:
11015155
19.

Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata.

Reekie J, Gatell JM, Yust I, Bakowska E, Rakhmanova A, Losso M, Krasnov M, Francioli P, Kowalska JD, Mocroft A; EuroSIDA in EuroCoord.

AIDS. 2011 Nov 28;25(18):2259-68. doi: 10.1097/QAD.0b013e32834cdb4b.

PMID:
21918422
20.

Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration.

Gabillard D, Lewden C, Ndoye I, Moh R, Segeral O, Tonwe-Gold B, Etard JF, Pagnaroat M, Fournier-Nicolle I, Eholié S, Konate I, Minga A, Mpoudi-Ngole E, Koulla-Shiro S, Zannou DM, Anglaret X, Laurent C; ANRS 12222 Morbidity Mortality Study Group.

J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):555-61. doi: 10.1097/QAI.0b013e3182821821.

Supplemental Content

Support Center